More on the Australian advantage: up to 43.5% cash back for every $1 spent on R&D in Australia
When it comes to places to conduct research, few places globally offer better incentives than Australia.
Known as the “Australian advantage”, not only does the land down under offer a fast and pragmatic regulatory environment for clinical studies (with a review and approval process taking only 4-6 weeks for healthy volunteer studies), but it also offers a host of other incentives such as:
- The Australian Regulatory Framework: CTN scheme 4-8 weeks for review, less than 12 weeks for study start-up
- No requirement for IND
- Melbourne, Victoria (where Crux is located) is a recognised leader in early-stage clinical trials, known for the quality of its clinical sites and the clinician expertise that facilitates the timely execution of excellent clinical trials
- Data generated at Crux Biolabs is ICH, FDA and EMA compliant and accepted for Phase 1 & 2 studies conducted globally
- And, of course, the famous “up to 43.5% cash back for every $1 spent in R&D in Australia” incentive.
With that in mind, note that we here at Crux Biolabs are a registered Research Service Provider with the Australian Government which allows easy claims for said R&D Tax, available to international and local sponsors.
To find out more, get in touch with us through this link about how we can help you – and in navigating the Australian advantage for your own research project.